MED-LATANOPROST SOLUTION

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

LATANOPROST

متاح من:

GENERIC MEDICAL PARTNERS INC

ATC رمز:

S01EE01

INN (الاسم الدولي):

LATANOPROST

جرعة:

50MCG

الشكل الصيدلاني:

SOLUTION

تركيب:

LATANOPROST 50MCG

طريقة التعاطي:

OPHTHALMIC

الوحدات في الحزمة:

2.5ML/5ML

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

PROSTAGLANDIN ANALOGS

ملخص المنتج:

Active ingredient group (AIG) number: 0132916002; AHFS:

الوضع إذن:

APPROVED

تاريخ الترخيص:

2014-07-30

خصائص المنتج

_Page 1 of 28_
_MED-LATANOPROST (Latanoprost)_
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
MED-LATANOPROST
Latanoprost ophthalmic
solution
Solution, 50 mcg/mL, Ophthalmic
Prostaglandin F
2α
analogue
Generic Medical Partners Inc.
251 Consumers Road Suite 1200
Toronto, Ontario
M2J 4R3
Date of Initial Authorization:
June 25, 2014
Date of Revision:
July 27, 2023
Submission Control Number: 273339
_Page 2 of 28_
_MED-LATANOPROST (Latanoprost)_
_ _
RECENT MAJOR LABEL CHANGES
None at the time of most recent authorization
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.1
Dosing Considerations
...............................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
......................................................... 4
4.4
Administration
..........................................................................................................
5
4.5
Missed Dose
........................................